The Test License for Medical Devices in India Document Requirements are now clearly defined by the Central Drugs Standard Control Organisation, giving U.S. companies a straightforward roadmap for medical device regulation, CDSCO approval, India market entry, clinical trial testing, and regulatory compliance India in 2026. Whether you are manufacturing small batches locally or importing prototypes for evaluation, the CDSCO has standardized the exact documents needed for both Form MD-12 (manufacturing test licence) and Form MD-16 (import test licence). These licences allow non-commercial testing, validation, clinical investigation, or demonstration without triggering full commercial licensing rules.
The process is handled entirely online through the SUGAM portal, making it faster and more predictable for American medtech firms. Once approved, the licence (issued as Form MD-13 for manufacturing or Form MD-17 for import) is valid for three years. Every device must carry the clear label “For Testing Purposes Only – Not for Sale.” Violating this rule can lead to licence cancellation, fines, or seizure of the devices. Testing can be performed at the applicant’s own facility or at a registered Medical Device Testing Laboratory if needed.
The core document checklist is identical regardless of device risk class (A, B, C, or D) because the licence is strictly for non-commercial use. Applicants must upload the following on the SUGAM portal:
- A formal covering letter that clearly states the intent (e.g., “Application for Test License for [Device Name]”) and the specific objective, such as clinical investigation or performance evaluation.
- A brief description of the device, including its intended use, technical specifications, and key features.
- A detailed justification of quantity that explains exactly why the requested number of units is necessary for the proposed tests.
- The test specification and protocol, including the applicable standards (ISO, IEC, or ASTM) and the exact methods that will be followed.
- Evidence of a quality management system (such as ISO 13485 certification) for the manufacturing site to prove facility adequacy.
- A signed undertaking (Form-16 or Form-12) declaring that the devices will be used exclusively for testing and will not be sold commercially.
- For manufacturing applications (MD-12), a brief manufacturing or testing flowchart plus a list of qualified technical personnel involved.
- Drafts of the device labels and Instructions for Use (IFU), with every label clearly marked “For Testing Purposes Only.”
Higher-risk Class C and D devices may require more detailed Device Master Files and Plant Master Files if the data generated will later support a full commercial licence (Form MD-9). If the device has no predicate in India, applicants may also need to file Form MD-26 for clinical investigations.
U.S. companies are already using this checklist to move prototypes into India faster and cheaper than ever before. The low fees — approximately ₹500 per device for manufacturing and roughly $100 USD per device for imports as of April 2026 — combined with 30-to-60-day approval timelines make the process highly attractive for firms based in Minnesota’s Medical Alley, California’s Silicon Valley, or Massachusetts’ Route 128 corridor.
The licence fits perfectly into India’s broader push to become a global medtech hub. With the country’s medical device market growing rapidly and the CDSCO tightening rules for full commercial approvals, the test licence serves as the essential first step for generating credible local data. Many U.S. firms now view it as a strategic tool that lowers overall development costs and reduces supply-chain risk by allowing early validation closer to the target market.
Regulatory consultants working with American clients say early preparation of these documents is key. “Having the complete checklist ready before you log into the SUGAM portal can cut approval time in half,” said Dr. Priya Sharma, who advises several Fortune 500 medtech companies. On industry forums and LinkedIn, U.S. regulatory teams are sharing success stories, with many noting that the digital portal and standardized requirements have made India far more accessible than it was just two years ago.
For U.S. businesses, the impact is immediate and financial. The licence reduces the need for expensive third-party testing labs in Europe or the United States and helps companies meet “Make in India” incentives while building relationships with local clinical partners. In an election year when healthcare affordability remains a top voter concern, any pathway that helps control device development costs draws attention from both industry leaders and policymakers.
The CDSCO has signaled further upgrades to the SUGAM portal later in 2026, including AI-assisted application reviews and real-time tracking. Companies that prepare the full document checklist now will be best positioned to capitalize on these improvements and potential trade incentives.
The Test License for Medical Devices in India Document Requirements have given U.S. companies a clear, low-cost, and predictable route for medical device regulation, CDSCO approval, India market entry, clinical trial testing, and regulatory compliance India in 2026. With the SUGAM portal making the process more transparent than ever, the window for smart, strategic entry is wide open.
By Mark Smith
Follow us and subscribe now — turn on push notifications to never miss a breaking U.S. news update. Join our WhatsApp channel and social media pages for real-time alerts.